Quince Therapeutics (QNCX) Competitors $1.82 +0.04 (+2.25%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.88 +0.06 (+3.30%) As of 07/11/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNCX vs. AARD, OLMA, LIMN, OCGN, ZYBT, GOSS, GLUE, CRVS, RNAC, and ADCTShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Aardvark Therapeutics (AARD), Olema Pharmaceuticals (OLMA), Liminatus Pharma (LIMN), Ocugen (OCGN), Zhengye Biotechnology (ZYBT), Gossamer Bio (GOSS), Monte Rosa Therapeutics (GLUE), Corvus Pharmaceuticals (CRVS), Cartesian Therapeutics (RNAC), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Its Competitors Aardvark Therapeutics Olema Pharmaceuticals Liminatus Pharma Ocugen Zhengye Biotechnology Gossamer Bio Monte Rosa Therapeutics Corvus Pharmaceuticals Cartesian Therapeutics ADC Therapeutics Quince Therapeutics (NASDAQ:QNCX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Does the media refer more to QNCX or AARD? In the previous week, Quince Therapeutics had 1 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 3 mentions for Quince Therapeutics and 2 mentions for Aardvark Therapeutics. Quince Therapeutics' average media sentiment score of 0.94 beat Aardvark Therapeutics' score of 0.45 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, QNCX or AARD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$56.83M-$1.39-1.31Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A Is QNCX or AARD more profitable? Aardvark Therapeutics' return on equity of 0.00% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -117.52% -34.22% Aardvark Therapeutics N/A N/A N/A Do institutionals and insiders believe in QNCX or AARD? 30.8% of Quince Therapeutics shares are owned by institutional investors. 20.3% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer QNCX or AARD? Quince Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 339.56%. Aardvark Therapeutics has a consensus target price of $33.00, indicating a potential upside of 171.16%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Quince Therapeutics is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryQuince Therapeutics beats Aardvark Therapeutics on 7 of the 10 factors compared between the two stocks. Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.93M$2.97B$5.62B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-1.3120.5828.0020.27Price / SalesN/A292.05429.5999.28Price / CashN/A42.8637.4658.16Price / Book2.647.638.045.49Net Income-$56.83M-$55.05M$3.18B$250.45M7 Day Performance13.40%8.39%3.60%4.73%1 Month Performance51.67%5.35%4.00%7.61%1 Year Performance133.87%1.95%29.52%16.39% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics3.3658 of 5 stars$1.82+2.2%$8.00+339.6%+109.7%$80.93MN/A-1.3160News CoverageAARDAardvark TherapeuticsN/A$13.52+1.0%$33.00+144.1%N/A$293.38MN/A0.0018OLMAOlema Pharmaceuticals2.4236 of 5 stars$4.26-7.8%$24.50+475.1%-62.8%$291.47MN/A-2.1270Positive NewsLIMNLiminatus PharmaN/A$11.15+17.6%N/AN/A$290.01MN/A0.00N/APositive NewsAnalyst UpgradeGap DownOCGNOcugen1.5116 of 5 stars$0.97-1.4%$6.00+518.3%-38.0%$283.39M$4.05M-5.1180High Trading VolumeZYBTZhengye BiotechnologyN/A$5.97-9.7%N/AN/A$281.61MN/A0.00278Positive NewsLockup ExpirationGap DownGOSSGossamer Bio3.8398 of 5 stars$1.23-1.6%$7.33+496.2%+10.6%$279.58M$114.70M-5.35180GLUEMonte Rosa Therapeutics2.0442 of 5 stars$4.51-2.0%$15.33+240.0%+27.1%$277.41M$75.62M56.3890Positive NewsCRVSCorvus Pharmaceuticals2.8687 of 5 stars$4.00+2.8%$15.00+275.0%+109.1%$272.68MN/A-4.0830Positive NewsRNACCartesian Therapeutics2.2661 of 5 stars$10.39-2.7%$41.25+297.0%-25.0%$269.66M$34.17M-0.2064News CoveragePositive NewsAnalyst ForecastAnalyst RevisionADCTADC Therapeutics1.2771 of 5 stars$2.69-0.7%$7.75+188.1%-16.5%$266.79M$70.84M-1.86310 Related Companies and Tools Related Companies Aardvark Therapeutics Alternatives Olema Pharmaceuticals Alternatives Liminatus Pharma Alternatives Ocugen Alternatives Zhengye Biotechnology Alternatives Gossamer Bio Alternatives Monte Rosa Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Cartesian Therapeutics Alternatives ADC Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNCX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QNCX Stock Alerts